Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177 Lu-labeled prostate-specific membrane antigen

ConclusionThe presented predictive score allowed a pre-therapeutic estimate of the expected response to 2 cycles of RLT. As our study was retrospective, prospective trials are needed for validation.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research